Industry

SynBalance Srl secures dual honors at 2024 NutraIngredients Awards

The company was honored with the Ingredient of the Year award in the Microbiome Modulation and the Beauty from Within category.

Biompharma’s Bi104 Receives FDA Orphan Drug Designation for Angelman Syndrome Treatment

Bi104 is a microbiome-modifying biologic designed to diversify and modulate the gut microflora and metabolite profile.

Miquel Bonachera discusses AB-BIOTICS’ new role on the IPA Board of Directors

AB-Biotics recently appointed to the IPA board of directors. What opportunities and future developments? We discussed this with Miquel Bonachera.

Explore the future of wellness with SynBalance at Vitafoods

Join SynBalance at Vitafoods Europe 2024, held at Palexpo, Switzerland from May 14th to May 16th.

Novo Nordisk Foundation, Wellcome, and Gates Foundation Forge Alliance to Tackle Microbiome Challenges

This unprecedented partnership signifies a concerted effort to address pressing microbiome-related challenges and advance health equity worldwide.

Nutrigenomics: from Biofarma an innovative approach to cardiometabolic diseases

Biofarma Group has consolidated its expertise in the formulation of dietary supplements aimed at cardiometabolic well-being.

New era in infant nutrition: Lallemand Health Solutions and DSM-Firmenich formulate synbiotic solutions

Isabelle Champié: “At Lallemand Health Solutions, we are committed to pushing the boundaries of probiotic research and development to create solutions that promote optimal health and well-being.

Flow cytometry: from Biofarma Group, a new approach for probiotic counting

A team of researchers have carried out a study on the search for bacterial probiotics, using a new method: flow cytometry

Advanced long-read sequencing services revolutionize microbiome analysis

Clinical Microbiomics sets a new standard in microbial research with unmatched data precision and resolution.

Sacco System unveils new biotech development site in Brisbane

Sacco System announces the grand opening of its development site in Australia.

Subscribe to MicrobiomePost newsletter

Take full advantage of MicrobiomePost‘s features.

Scroll to Top